UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 19, 2021
Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-35527 |
|
87-0419387 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
| 21250 Hawthorne Boulevard, Suite 800, Torrance, CA |
|
90503 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code (310) 214-0065
(Former name or former address, if changed, since last
report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol |
|
Name of each exchange
on which registered |
| None |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
On May 4, 2021, Emmaus Life Sciences, Inc. (“we,”
“us,” “our,” “Emmaus” or the “company”) filed with the U.S. Securities and Exchange Commission
our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Form 10-K”). The Form 10-K contained a qualified
audit report of Baker Tilly US, LLP (“Baker Tilly”), the company’s independent registered public accounting firm, on
the company’s financial statements as of and for the fiscal year ended December 31, 2020 (the “2020 Financial Statements”).
As indicated in its report, Baker Tilly was unable to obtain audited financial statements supporting
the company's equity in losses in a privately held foreign affiliate of $2,314,000 included in the company’s reported net income
of $1,100,000 and comprehensive income of $2,316,000 for the year ended December 31, 2020; nor were they able to satisfy themselves as
to the equity in losses in the foreign affiliate by other auditing procedures. We have determined that in light of Baker Tilly’s
qualified audit report the 2020 Financial Statements do not meet the requirements of Regulation S-X Article 2. Consequently, we are not
current in our SEC reporting obligations notwithstanding the filing of the Form 10-K.
The company intends to undertake to audit the financials
of the foreign affiliate to remedy the underlying deficiency that gave rise to Baker Tilly’s qualified audit report. Except for
the qualified audit report, we believe the Form 10-K complies in form and content with the SEC’s requirements.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
The exhibit listed on the accompanying Index to Exhibits
is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 19, 2021 |
EMMAUS LIFE SCIENCES, INC. |
| |
|
|
| |
By: |
/s/ YASUSHI NAGASAKI |
| |
Name: |
Yasushi Nagasaki |
| |
Title: |
Interim Chief Financial Officer |
INDEX TO EXHIBITS
